CTOs on the Move

Warner Chilcott, P.L.C.

www.wcrx.com

 
Warner Chilcott, P.L.C. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.wcrx.com
  • 100 Enterprise Dr Ste 280
    Rockaway, NJ USA '07866
  • Phone: 973.442.3200

Executives

Name Title Contact Details

Similar Companies

Lumate Health

Lumate Health is a Cognitive Behavioral Teletherapy Platform treating teenagers and young adults with anxiety-related mental health disorders.

RxHub

RxHub LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Asian Health Services

We offer medical, dental and behavioral health care for Alameda Countys underserved Asian and Pacific Islander community.

Nabriva

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. Nabriva was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria and commenced operations in February 2006. The new organization included small molecule assets, including pleuromutilin structure activity relationships (SAR) knowledge and was focused on synthesis of pleuromutilins for systemic human use. Following identification of our lead compound lefamulin and based on the clinical results of lefamulin for Acute Skin and Skin Structure Infections. We believed that targeted in vitro spectrum of activity for the common pathogens causing Community Acquired Bacterial Pneumonia (CABP), would allow us to develop lefamulin as the first pleuromutilin IV and oral antibiotic for human systemic administration for CABP. In 2014, we opened our US office in King of Prussia, Pennsylvania and completed an IPO on the NASDAQ under the ticker NBRV in September 2015. With net proceeds from our IPO, we initiated two global, registrational Phase 3 clinical trials of lefamulin for the treatment of moderate to severe CABP. Based on our estimates regarding patient enrollment, we expect to have top-line data available for both trials in the second half of 2017. If the results of these trials are favorable, including achievement of the primary efficacy endpoints of the trials, we expect to submit applications for marketing approval for lefamulin for the treatment of CABP in both the United States and Europe in 2018. As of April 1, 2016, Nabriva employed 52 employees at its headquarters in Vienna, Austria, and its office in King of Prussia, Pennsylvania, United States.

U.S. Dermatology Partners

We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.